Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note

Humacyte, Inc. (HUMA) stock fell 12.11% on November 5, 2026, significantly outpacing the broader market decline of 4.36%. The company is scheduled to report earnings on November 10, 2026, with projected EPS of -$0.09 and revenue of $0.86 million. For the full year, Zacks projects earnings of -$0.4 per share and revenue of $4.05 million. The stock currently holds a Zacks Rank of #3 (Hold).